PA
LRMR icon

Perceptive Advisors’s Larimar Therapeutics LRMR Stock Holding History

Perceptive Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,280,709
Closed -$10.3M – 103
2023
Q1 		$10.3M Sell
2,280,709
-579,291
-20% -$3.03M 0.31% 65
2022
Q4 		$11.8M Hold
2,860,000
– – 0.33% 59
2022
Q3 		$9.15M Buy
+2,860,000
New +$7.16M 0.27% 68
2015
Q1 		– Sell
-23,193
Closed -$8.58M – 164
2014
Q4 		$8.58M Buy
23,193
+276
+1% +$71.1K 0.72% 35
2014
Q3 		$5.4M Buy
+22,917
New +$5.19M 0.55% 45

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Perceptive Advisors's LRMR Position: Q2 2023 in Review

Perceptive Advisors sold out of Larimar Therapeutics (LRMR) in Q2 2023, closing a stake of 2,280,709 shares — an estimated $10.3M sold.

Perceptive Advisors first reported a position in LRMR in Q3 2014 and held it in 5 quarters. The position peaked at $11.8M in Q4 2022. 65 funds tracked by Wall St. Rank hold LRMR as of Q2 2023.

  • Perceptive Advisors reported no remaining Larimar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Perceptive Advisors sold 2,280,709 Larimar Therapeutics shares in Q2 2023, an estimated $10.3M.
  • Perceptive Advisors first reported a position in Larimar Therapeutics in Q3 2014 and held it in 5 quarters.
  • Perceptive Advisors's Larimar Therapeutics position peaked at $11.8M in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2023.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.